# Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol

> **NCT01265264** · PHASE2 · COMPLETED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 279 (actual)

## Conditions studied

- Gout
- Hyperuricemia
- Arthritis
- Joint Disease

## Interventions

- **DRUG:** ulodesine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01265264
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-07
- **Final completion:** 2013-02
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2013-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01265264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01265264, "Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01265264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*